Med Ed Report briefs

Cephalon reported 2009 payments to physician consultants and speakers, as required by a corporate integrity agreement. The CIA was imposed as part of a $444 million settlement of an off-label marketing case in 2008. The report shows that the company's top-paid physician earned $149,900 in 2009, 17 earned over $100,000 from the company last year.

John Hopkins' Dr. Todd Dorman wrote in the AMA's CPPD Report that CME was enjoying a “usual state of good health until media, government and regulatory agencies began to question the veracity of CME programs and the transparency of their process.” Dorman, associate dean and director of the school's office of CME, said CME suffers from “a case of systemic inflammatory response syndrome,” with investigations casting a pall on CME funding and programs instead of the few physicians that have improperly reported payments.

The ACCME issued a call for comment on a proposal for balancing transparency and confidentiality in the complaints and inquiries process by which ACCME investigates issues of commercial bias or content validation. The group has gotten conflicting feedback—some arguing for transparency, others for more confidentiality.

You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.